Bristol Myers Squibb Acquires Orbital Therapeutics for $1.5B
- SSCTR Exco
- Oct 12
- 1 min read
Published on LinkedIn (via Spencer Knight)
Bristol Myers Squibb announced a $1.5 billion acquisition of Orbital Therapeutics, advancing its cell therapy platform into the in vivo era. The deal adds Orbital’s RNA- and AI-driven platform that enables CAR T cell generation directly inside the body, potentially transforming how autoimmune and oncology treatments are delivered.
👉 Read the full post: BMS to Acquire Orbital Therapeutics for $1.5B
Disclaimer
Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.
Comments